Roth Capital raised the firm’s price target on Zimmer Biomet (ZBH) to $138 from $135 and keeps a Buy rating on the shares after Q2 adjusted EPS topped consensus and guidance was raised. With the second half set to accelerate, the firm raised its own 2026 EPS estimate to $8.66 from a prior $8.34 forecast.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZBH:
- Zimmer Biomet Holdings: Hold Rating Maintained Amid Modest Growth and Market Shifts
- Early notable gainers among liquid option names on August 7th
- Morning Movers: Apple adds to yesterday’s gains, Trump calls out Intel CEO
- Zimmer Biomet reports Q2 adjusted EPS $2.07, consensus $1.98
- Zimmer Biomet raises FY25 adjusted EPS view to $8.10-$8.30 from $7.90-$8.10